Telix Pharmaceuticals announces launch of Renal cancer imaging study
Category: #health  By Mateen Dalal  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Pharmaceuticals announces launch of Renal cancer imaging study
  • The pharmaceutical company declared the completion of CTN submission to Japanese PMDA for TLX250-CDx.
  • It is permitted to conduct Phase trials for renal cancer patients.

Australia based clinical-stage biopharmaceutical firm Telix Pharmaceuticals reportedly announced successful completion of a Clinical Trial Notification submission to the Japanese Pharmaceutical & Medical Devices Agency for TLX250-CDx.

For the uninitiated, Telix Pharmaceuticals Limited, headquartered in Australia is a biopharmaceutical company working towards the development of diagnostic and therapeutic products dependent on radiopharmaceuticals.

Reportedly, the company’s owned subsidiary Telix Japan had submitted the CTN at the July end following a robust consultation process with the PMDA. It has been claimed that the company tried resolving the PMDA’s remaining questions whilst collaborating with the other major shareholders like the Ministry of Health, and Labour and Welfare (MHLW).

As per trusted reports, Telix is now allowed to initiate a study designed to extend the company’s global ZIRCON Phase 3 investigation. It has been claimed that the study would register over 40 renal cancer patients. The phase 2 is expected to grow to a multi-focus study whilst operating under a procedure that is considered to be accurately identical to the ZIRCON investigation.

Speaking on the trial, the President of Telix Japan, Dr. Shintaro Nishimura reportedly stated that the company believes that CTN would wholly transform the face of the Japanese Nuclear Medicine community accounting to its first formal clinical investigation for the zirconium PET imaging in Japan. Additionally, TLX250-CDx offers an incredible potential to offer benefits to the cancer patients which would eventually help make way for impending use of theranostics in the country.

Meanwhile, the CEO of the company, Dr, Christian Behrenbruch cited that Telix has introduced a major amount to effort to accomplish the study and make it function in the states of Japan along with manufacturing the radiopharmaceutical products domestically within confined governing environment. Furthermore, the company is grateful to its clinical and finance partners for their constant support and involvement.

Source credit: https://www.globenewswire.com/news-release/2019/08/30/1908793/0/en/Telix-Pharmaceuticals-to-Launch-Japanese-Renal-Cancer-Imaging-Study.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Roches risdiplam meets primary endpoint results in phase 3 trial
Roches risdiplam meets primary endpoint results in phase 3 trial
By Mateen Dalal

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective ...

Disney+ all set for a March 2020 launch in the United Kingdom
Disney+ all set for a March 2020 launch in the United Kingdom
By Mateen Dalal

The entertainment behemoth is launching its much-awaited streaming platform.   Release of more than 300 movies is on the cards. Disney has finally asserted that new streaming service Disney+ will be rolled out soon in the U.K. Disney+ goes...

AB Science receives Orphan Drug Designation from the FDA for AB8939
AB Science receives Orphan Drug Designation from the FDA for AB8939
By Mateen Dalal

AML (acute myeloid leukemia), a severe, life-threating disease that is one of the most common causes of cancer-related death. Common treatment options for this condition includes stem-cell transplants, chemotherapy and other drug therapy. However, wi...